Viking Therapeutics
NEWS
Tuesday, Viking Therapeutics released Phase I results for its weight-loss candidate VK2735, which demonstrated a good safety and tolerability profile and resulted in significant weight reductions.
The FDA is calling the study a phase II trial and says the company must run a rodent genotoxicity study before it can continue.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, SVP of finance.
For years, companies have struggled to develop treatments for non-alcoholic fatty liver disease (NAFLD), a disease that is growing across the world and is predicted to become the main cause of chronic liver problems and the need for liver transplantation.
As the International Liver Conference continues to unfold in Vienna, multiple companies are presenting data on potential treatments that can address numerous needs. BioSpace takes a look at some of the data.
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.
JOBS
IN THE PRESS